Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Herpes simplex virus is known to induce an immunoglobulin-binding cell surface receptor in infected cells that utilizes a nonimmune mechanism. In the present paper, we report the immunoglobulin class and subclass specificity of this receptor. Of the human immunoglobulins G(IgG), IgA, IgM, and IgD, as well as the structurally related beta2 microglobulin, only IgG and its Fc portion exhibited an increased binding to herpes simplex virus-infected cells versus uninfected control cells. The IgG subclass specificity of the Fc receptor was studied in 37 radioiodinated IgG myeloma proteins representing all four subclasses. We found that IgG3 myeloma proteins did not bind to herpes simplex virus-infected cells to a greater extent than to uninfected cells. On the contrary, proteins belonging to the other subclasses exhibited an increased binding to herpes simplex virus-infected cells of the following relative magnitude: IgG4 greater than IgG1 greater than or equal to IgG2. This increment of binding could be abolished by addition of a large excess of human IgG Fc fragment. Evidence for the existence of a variable herpes simplex virus-specific binding ability between myeloma proteins belonging to the same IgG subclass was also obtained. Furthermore, we tested two other herpes simplex virus type 1 strains with a limited number of myeloma proteins with very similar results as with the herpes simplex virus type 1 F strain. Several sources of experimental artefacts were controlled, including the state of aggregation of the test proteins, the functional integrity of the Fc portion before and after radioiodination, and the subclass assignments. The implications for the biological role of the Fc receptor of herpes simplex virus are discussed.
 ...
PMID:Human immunoglobulin class and subclass specificity of Fc receptors induced by herpes simplex virus type 1. 632 9

Serum beta 2m binding activity (S beta 2m-BA) was determined by a polyethylene glycol exclusion test of radiolabeled human beta 2m in 185 serum samples from 62 patients with multiple myeloma (MM). Elevated S beta 2m-BA was found in more than half of the samples from IgG myeloma taken before treatment or during progression of the disease but not during the plateau-phase. Conversely, elevated S beta 2m-BA was found in only one case of IgA myeloma, one case of monoclonal gammopathy of undetermined significance and none of the Bence Jones myelomas. S beta 2m-BA appears to be related to disease progression in IgG myeloma. The activity is supported by minute amounts of serum autoantibodies which are distinct from the monoclonal component. S beta 2m-BA was independent from serum beta 2m levels.
 ...
PMID:Serum beta-2-microglobulin binding activity in monoclonal gammopathy: correlative study and clinical significance. 635 77

The effect of IgE soluble immune complex (SIC) and IgG SIC on neutrophil chemotaxis was investigated. Eight types of SIC were prepared from kappa type IgE myeloma protein and IgG myeloma protein: IgE-anti-kappa SIC in IgE excess and in anti-kappa excess, IgE-anti-epsilon SIC in IgE excess and in anti-epsilon excess, IgG-anti-kappa SIC in IgG excess and in anti-kappa excess, IgG-anti-gamma SIC in IgG excess and in anti-gamma excess. Four types of IgE SIC markedly suppressed neutrophil and chemotaxis, but free IgE, free anti-kappa chain antibody, free anti-epsilon chain antibody and IgG SIC had no inhibitory activity. This inhibitory activity of IgE SIC on neutrophil chemotaxis was cell directed and concentration-dependent. IgE immune complex also inhibited neutrophil chemotaxis when immune complex was formed in the neutrophil chemotaxis.
 ...
PMID:Suppressive effect of IgE soluble immune complex on neutrophil chemotaxis. 640 74

Seventeen patients with multiple myeloma were given intravenous immunoglobulin at doses ranging from 150 mg/kg to 500 mg/kg in a phase I study. The intravenous immunoglobulin was well tolerated with only three transient episodes of mild clinical toxicity during 27 infusions. In no instance was hepatic or renal toxicity seen. Marked biologic variability over the one month study period in total IgG levels in patients with non-IgG myeloma and IgG subclasses in many of the patients was observed, making intravenous immunoglobulin half-life determinations based on IgG or IgG subclass levels problematical. The decay of functional antibody to hepatitis B surface antigen was determined. Analysis of the hepatitis antibody data suggested that intravenous immunoglobulin half-life was in the range of seven to 20 days for the entire study group and was not related to the isotype of the myeloma paraprotein or to the baseline levels of IgG. No infections were observed in the study group during the study period, but the potential for infection prophylaxis by intravenous immunoglobulin in myeloma patients must be evaluated in a randomized, prospective, controlled phase III study.
 ...
PMID:Phase I study of intravenous gamma globulin in multiple myeloma. 642 42

Peripheral blood mononuclear cells (PBM) from four patients with IgG myeloma and four patients with benign monoclonal gammopathy (BMG) were stimulated with pokeweed mitogen (PWM), and the in vitro immunoglobulin production over 7 days was measured with an enzyme-linked immunosorbent assay. All myeloma patients were sufficiently treated with cytostatic drugs. Their PBM did not produce monoclonal Ig in vitro, as opposed to PBM from two patients with BMG. Unseparated PBM from myeloma patients produced smaller amounts of polyclonal Ig than unseparated cells from normal donors. However, macrophage-depleted PBM from myeloma patients produced amounts of Ig comparable to those of normal donors when autologous or allogeneic adherent cells were returned in defined numbers. T cells from three of the four myeloma patients could provide help for the Ig production by B cells from healthy donors. These results indicate that functionally normal polyclonal B cells circulate in the blood of myeloma patients. The circulating T-cell population also has no obvious defect. In contrast, blood macrophages seemed to be altered with respect to their regulating function for polyclonal Ig production. The results obtained by using cell populations from patients with BMG did not differ from those of healthy people.
 ...
PMID:In vitro immunoglobulin production by peripheral blood mononuclear cells from multiple myeloma patients and patients with benign monoclonal gammopathy. Regulation by cell subsets. 653 40

Twenty-three cases of hematological malignancies (18 plasma cell neoplasm, 2 leukemia and 2 malignant lymphoma) were treated with recombinant human leukocyte interferon (rIFN-alpha A). Among plasma cell neoplasms, excellent and good responses were obtained in 1 case of IgG myeloma and 1 case of Bence-Jones myeloma respectively and fair response was obtained in 5 other cases. Response rats was 11.4%, or 38.9% if fair response was included. Partial remission was obtained in 1 case of chronic lymphocytic leukemia. In one of 2 cases of acute lymphoblastic leukemia, marked reduction of peripheral leukemia cells was noted. Side effects included fever (65%), malaise (20%), nausea-anorexia (43%), leukopenia (52%) and thrombocytopenia (52%). However, all were not serious and disappeared quickly after discontinuation of rIFN-alpha A.
 ...
PMID:[Treatment of hematological malignancies with recombinant leukocyte A interferon (rIFN-alpha A)]. 659 73

A case of IgG myeloma with eburnation of the femoral and ileoischiopubic bones is described. A review of the literature confirmed the rarity of osteosclerotic myeloma, especially if other possible causes of bone eburnation or the typical contemporary existence of osteolysis are excluded. The hypothesis that osteosclerotic myeloma may constitute an autonomous form of the disease, probably related to the type and/or extent of the proliferating bone is discussed.
 ...
PMID:[The osteocondensing variety of multiple myeloma. Review of the literature and description of a case]. 664 80

The presence of J chain in human immunocytes containing various immunoglobulin classes has already been reported and in this paper we investigated the presence of J chain in human myeloma cells using light and electron microscopy. Myeloma cells were positive for cytoplasmic J chain in thirteen cases: six of fifteen IgG myeloma, two of seven IgA myeloma, two of nine B-J myeloma and three of three primary macroglobulinaemia. None of the four with benign monoclonal gammopathy was positive for J chain. The ultrastructural localization of J chain in IgG myeloma cells was similar to that of gamma chain, i.e. around the nuclear membrane, in the endoplasmic reticulum (ER) and in the Golgi apparatus. The latter finding is compatible with the presence of J chain in the urine of the same patient. We examined the urine from nine patients with J chain-positive cells and secretion of J chain was confirmed in three patients: two with IgG myeloma and one with B-J myeloma. In noe of twelve in whom the immunocytochemical findings were negative for J chain was there evidence of urinary J chain.
 ...
PMID:J chain synthesis in human myeloma cells: light and electron microscopic studies. 677 44

Individual specific antisera were raised against the monoclonal serum component from six IgG myeloma patients. Idiotypic (Id) determinants were identified in direct or indirect immunofluorescence (IFL) on 0.5-44% B lymphocytes from five patients with active disease. Id determinants were not detected on B lymphocytes from one IgG-k myeloma patient with an imbalance in the expression of upsilon heavy chains and kappa light chains. Nor were Id determinants detected on E-rosetting cells. Id structures were usually present together with upsilon chains on monoclonal B lymphocytes, some of which also carried mu and/or delta chains. Blood cells with lymphoplasmacytoid appearance were abundant in two patients. These cells carried IgG with Id determinants both in the cytoplasm and on the surface. Fc receptors were present on most cells carrying surface Id structures but were rare on cells with cytoplasmic monoclonal characteristics. The results further support the hypothesis of multiple myeloma as a differentiating B-lymphocyte tumour.
 ...
PMID:Monoclonal B lymphocytes in multiple myeloma. 678 Oct 65

In 12 myeloma patients responding to chemotherapy (7 IgG and 5 IgA), we studied the effect on the anion gap of a 50% reduction in the serum paraprotein concentration. In contrast to the pretreatment anion gap which was decreased in IgG myeloma and increased in IgA myeloma, the value calculated when the paraprotein spike was halved showed a tendency towards normalization in the former type of myeloma, whereas it appeared as quite normalized in the latter. Our results lend further support to the conceptions that IgG and IgA paraproteins behave in the serum as cations and anions, respectively, and that serial determinations of the anion gap may be of value for monitoring the response to treatment in patients with multiple myeloma.
 ...
PMID:Effect of chemotherapy on the anion gap in multiple myeloma. 679 96


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>